Eversana – a leading independent provider of global, commercial services to the life science industry – announced the expansion of the company’s channel management and 3PL (third party logistics) operation with the addition of a new 260,000 square foot Verified-Accredited Wholesale Distributor (VAWD) certified distribution center in Memphis, Tennessee.
Heron Therapeutics Inc. announced positive topline results of a multi-center postoperative pain management study in which 51 patients undergoing total knee arthroplasty surgery received the investigational agent HTX-011 together with a scheduled postoperative regimen of generic, oral analgesics (acetaminophen and celecoxib).
Heron Therapeutics Inc. resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for the commercial-stage biotechnology company’s HTX-011, an investigational agent for the management of postoperative pain.
Bausch Health Companies Inc., together with wholly owned subsidiary Salix Pharmaceuticals Inc.’s licensor Alfasigma SpA, announced the filing of a lawsuit against Sandoz Inc. alleging patent infringement of 14 patents by the Novartis division’s submission of an Abbreviated New Drug Application for Xifaxan
(rifaximin) 550 mg tablets.
The U.S. Food and Drug Administration approved Janssen’s Darzalex (daratumumab) in combination with bortezomib, thalidomide and dexamethasone for newly diagnosed patients with multiple myeloma who are eligible for autologous stem cell transplant.
Abbott’s ARCHITECT STAT High Sensitivity Troponin-I blood test received clearance from the U.S. Food and Drug Administration to help identify heart attacks several hours sooner than standard troponin tests and help improve diagnosis in women.
Amgen announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (20120215) showed that the primary endpoint of event-free survival was met.
Mallinckrodt plc announced positive top-line results from the global biopharmaceutical company’s pivotal Phase 3 clinical trial of the investigational StrataGraft regenerative tissue.
The U.S. Food and Drug Administration approved Novo Nordisk’s Rybelsus (semaglutide) tablets 7 mg or 14 mg for adults with type 2 diabetes that along with diet and exercise may improve blood sugar.
Outcome Health launched “In These Rooms” – a bespoke campaign to transform the strategy of the industry from “point of care” to “moments of care.”
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com. 
October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!
